Samsung Group has expanded its position in the biosimilar filed, establishing 13 pipelines

Samsung Group has been accelerated in expansion of its biosimilar business.

Samsung has currently shown rapid movements in the biopharmaceutical industry market through ‘Samsung Bioepis,’ a biopharmaceutical development and sales company, and ‘Samsung Biologics,’ a biopharmaceutical product procurement company.

According to the Biotech Policy Research Center’s analysis result of the ‘present ...